Acotec Scientific Holdings Limited (HK:6669) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acotec Scientific Holdings Limited has received approval from the PRC National Medical Products Administration for its Paclitaxel-Eluting Coronary Balloon Dilatation Catheter, AcoArt Camellia. Clinical trials demonstrated its superior efficacy and safety for treating coronary artery lesions compared to control groups. The company plans to launch marketing activities in China when appropriate.
For further insights into HK:6669 stock, check out TipRanks’ Stock Analysis page.